Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged at least 18 years of age upon receipt of first COVID-19 vaccination.
Fully vaccinated with any FDA-authorized COVID-19 vaccination.
Diagnosed with MS.
Receiving ofatumumab at the time of either (or both) of the following:
1. Initial COVID-19 vaccination.
2. Booster vaccination.
Had a documented measurement of humoral response at least 2 weeks after completion of either (or both) of the following:
1. Full COVID-19 vaccination course.
2. Booster vaccine (among patients receiving ofatumumab at the time of the booster).
You may not be if
Received treatment with monoclonal antibodies to treat or prevent COVID-19 at any time between the first COVID-19 vaccination to within 6 months of the last COVID-19 vaccination (booster-inclusive).
Clareo Health | A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
